title: Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.
abstract: Although the past decade has seen a surfeit of new targeted therapies for renal cell carcinoma (RCC), no predictive molecular biomarker is currently used in routine clinical practice to guide personalized therapy as a companion diagnostic. Many putative biomarkers have been suggested, but none have undergone rigorous validation. There have been considerable advances in the biological understanding of RCC in recent years, with the development of accompanying molecular diagnostics that with additional validation, may be helpful for routine clinical decision making. In this review, we summarize the current understanding of predictive biomarkers in RCC management and also highlight upcoming developments of interest in biomarker research for personalizing RCC diagnostics and therapeutics.
authors.affiliation: Department of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore, Singapore.
authors.forename: Jason Yongsheng
authors.initials: JY
authors.lastname: Chan
authors.forename: Yukti
authors.initials: Y
authors.lastname: Choudhury
authors.forename: Min-Han
authors.initials: MH
authors.lastname: Tan
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D000066491:Clinical Decision-Making; D019468:Disease Management; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000628:therapy; D025202:Molecular Diagnostic Techniques; D011379:Prognosis; D040901:Proteomics / Q000379:methods; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor
keywords: angiogenesis; biomarker; cytokine; immunotherapy; renal cell carcinoma